title: How to manage patients with severe left ventricular dysfunction and valvular regurgitation.
abstract: OBJECTIVE
  The purpose of this study is to analyze treatment options for valvular regurgitation with severe left ventricular dysfunction.
  
  
  METHODS
  Results of valvular surgery in 98 patients with mitral or aortic regurgitation and severe systolic left ventricular dysfunction (LVD) were analyzed. Selection criteria were the absence of significant coronary heart disease and a resting ejection fraction (EF) < 40% for aortic and < 50% for mitral regurgitation.
  
  
  RESULTS
  In patients with aortic regurgitation (n = 46) operative mortality was higher but not significantly so than in a control group of 238 cases (6.5% vs. 3.4%). The actuarial survival rates at five and 10 years were 84% and 55% vs. 84% and 67%, respectively. Independent preoperative predictors of severe postoperative LVD were rheumatic etiology and increased left ventricular end-systolic diameter. In patients with mitral regurgitation (n = 52), operative mortality was not significantly different from that of a control group of 273 cases (3.8% vs. 2.6%), whether the surgical procedure was valve replacement or valve repair. Perioperative morbidity was frequent (30% of cases), mainly low cardiac output, after valve replacement. The actuarial survival rates at eight years were respectively for the groups with and without LVD: 81% and 89% after valve repair, 60% and 75% after valve replacement. Independent predictors of severe postoperative LVD were increased left ventricular end-systolic volume and the type of surgery. Better results were observed after valve repair.
  
  
  CONCLUSIONS
  It is concluded that a low EF is not a predictive factor of operative mortality but it influences late survival as do the degree of left ventricular dilatation, etiology in aortic and type of surgery in mitral regurgitation. Alternatives to valvular surgery have been envisaged but information on vasodilators in these patients is scant and results of heart transplantation are known only from a few small series.
authors.affiliation: Cardiology Department, Hopital Tenon, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Acar
authors.forename: P L
authors.initials: PL
authors.lastname: Michel
authors.forename: P
authors.initials: P
authors.lastname: Luxereau
authors.forename: S
authors.initials: S
authors.lastname: Abou Jaoude
authors.forename: P
authors.initials: P
authors.lastname: Cazaux
authors.forename: R
authors.initials: R
authors.lastname: Dorent
authors.forename: B
authors.initials: B
authors.lastname: Cormier
authors.forename: B
authors.initials: B
authors.lastname: Jung
authors.forename: A
authors.initials: A
authors.lastname: Vahanian
mesh_terms: D000328:Adult; D000368:Aged; D001022:Aortic Valve Insufficiency / Q000150:complications* / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D016027:Heart Transplantation; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications* / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D015996:Survival Rate; D014665:Vasodilator Agents / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications* / Q000503:physiopathology / Q000601:surgery*
chemical_list: D014665:Vasodilator Agents